Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer
Paolo Tarantino, Julieta Leone, Carlos Vallejo, Rachel A. Freedman, Adrienne G. Waks, Olga Martínez‐Sáez, Ana C. Garrido-Castro, Filipa Lynce, Nabihah Tayob, Nancy U. Lin, Sara M. Tolaney, José Pablo Leone, José Pablo Leone, José Pablo Leone
Abstract
To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use of chemotherapy significantly increased from 2010 to 2019 in patients with T1b and T1c tumors (p = 0.001 and p < 0.001, respectively). Receipt of chemotherapy was associated with improved breast cancer-specific survival (BCSS, adjusted hazard ratio = 0.70; p = 0.006), particularly in patients with T1c tumors (5-year BCSS 94.5% vs. 91.2%).
Topics & Concepts
MedicineBreast cancerHazard ratioTriple-negative breast cancerOncologyInternal medicineChemotherapyStage (stratigraphy)Retrospective cohort studyTriple negativeCancerPopulationGynecologyConfidence intervalPaleontologyBiologyEnvironmental healthBreast Cancer Treatment StudiesBreast Lesions and CarcinomasHER2/EGFR in Cancer Research